雷替曲塞联合奥沙利铂治疗晚期直肠癌的疗效分析  

Efficacy analysis of raltitrexed combined with oxaliplatin in the treatment of advanced rectal cancer

作　　者：屈中玉[1] 万里新[1] 刘扬帆[1] 陶海云[1] 赵得堡 孙星 QU Zhongyu;WAN Lixin;LIU Yangfan;TAO Haiyun;ZHAO Debao;SUN Xing(Department of Oncology,Nanyang Central Hospital,Nanyang 473009,He’nan,China)

机构地区：[1]南阳市中心医院肿瘤内科,河南南阳4730090

出　　处：《癌症进展》2022年第11期1180-1182,1186,共4页Oncology Progress

摘　　要：目的观察雷替曲塞联合奥沙利铂治疗晚期直肠癌的临床疗效。方法将170例晚期直肠癌患者根据治疗方式不同分为观察组(n=91)和对照组(n=79)。对照组采用氟尿嘧啶、亚叶酸钙联合奥沙利铂治疗,观察组采用雷替曲塞联合奥沙利铂治疗。对比两组患者的近期疗效及生活质量、血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原19-9(CA19-9)和糖类抗原72-4(CA72-4)]水平,并观察不良反应。结果观察组患者总有效率、疾病控制率均高于对照组,差异均有统计学意义(P﹤0.05)。观察组患者卡氏功能状态(KPS)改善率明显高于对照组,差异有统计学意义(P﹤0.01)。治疗前,两组患者血清CEA、CA19-9及CA72-4水平比较,差异均无统计学意义(P﹥0.05);治疗后,两组患者CEA、CA19-9及CA72-4水平均低于本组治疗前,且观察组患者CEA、CA19-9及CA72-4水平均低于对照组,差异均有统计学意义(P﹤0.05)。观察组患者不良反应总发生率明显低于对照组,差异有统计学意义(P﹤0.01)。结论雷替曲塞联合奥沙利铂治疗晚期直肠癌疗效显著,能够降低血清肿瘤标志物水平,改善患者生活质量,减少不良反应。Objective To observe the clinical efficacy of raltitrexed combined with oxaliplatin in the treatment of ad-vanced rectal cancer.Method A total of 170 patients with advanced rectal cancer were divided into observation group(n=91)and control group(n=79)according to different treatment methods.The control group was treated with fluoroura-cil,calcium folinate combined with oxaliplatin,and the observation group was treated with raltitrexed combined with ox-aliplatin.The short-term efficacy,quality of life,serum tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9),and carbohydrate antigen 72-4(CA72-4)]levels were compared between the two groups.The in-cidence of adverse events was also monitored.Result The overall response rate and disease control rate of the observa-tion group were higher than those of the control group,and the differences were statistically significant(P<0.05).The im-provement rate of Karnofsky performance status(KPS)in the observation group was significantly higher than that in the control group,and the difference was statistically significant(P<0.01).Before the treatment,there was no significant dif-ference in serum CEA,CA19-9,and CA72-4 levels between the two groups(P>0.05);after the treatment,the levels of CEA,CA19-9,and CA72-4 in the two groups were lower than those before the treatment,and the levels in the observa-tion group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse events in the observation group was significantly lower than that in the control group,and the differ-ence was statistically significant(P<0.01).Conclusion Raltitrexed combined with oxaliplatin could achieve remarkable effect in the treatment of advanced rectal cancer.The regimen could reduce the level of serum tumor markers,improve the quality of life of patients,and reduce adverse events.

关 键 词：雷替曲塞 奥沙利铂 晚期直肠癌 

分 类 号：R735.37[医药卫生—肿瘤]